Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
The British Journal of General Practice : the Journal of the Royal College of General Practitioners
|
August 28, 2003
The Beck Inventory--hidden cost
Jane Yeo
Lancet (London, England)
|
April 5, 2008
Abacavir and the potential risk of myocardial infarction
Amy Cutrell, Cindy Brothers, Jane Yeo, et al.
AIDS (London, England)
|
July 9, 2004
SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients
Joseph C Gathe, Prudence Ive, Robin Wood, et al.
Clinical Therapeutics
|
July 25, 2006
Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study
Joseph C Gathe, Robin Wood, Ian Sanne, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 10, 2004
A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir and lamivudine for treatment of HIV-infected patients
Robin Wood, Joseph Eron, Keikawus Arasteh, et al.
Antimicrobial Agents and Chemotherapy
|
December 25, 2003
Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients
Robin Wood, Keikawus Arasteh, Hans-Jürgen Stellbrink, et al.
Antimicrobial Agents and Chemotherapy
|
February 19, 2002
Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors
Michael Maguire, Denise Shortino, Astrid Klein, et al.
Lancet (London, England)
|
August 8, 2006
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial
Joseph Eron, Patrick Yeni, Joseph Gathe, et al.
The Journal of Infectious Diseases
|
December 11, 2012
Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study
Joseph J Eron, Bonaventura Clotet, Jacques Durant, et al.
The Journal of Antimicrobial Chemotherapy
|
June 12, 2009
Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance
Jean-Michel Molina, Mounir Ait-Khaled, Roberto Rinaldi, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
The British Journal of General Practice : the Journal of the Royal College of General Practitioners
|
August 28, 2003
The Beck Inventory--hidden cost
Jane Yeo
Lancet (London, England)
|
April 5, 2008
Abacavir and the potential risk of myocardial infarction
Amy Cutrell, Cindy Brothers, Jane Yeo, et al.
AIDS (London, England)
|
July 9, 2004
SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients
Joseph C Gathe, Prudence Ive, Robin Wood, et al.
Clinical Therapeutics
|
July 25, 2006
Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study
Joseph C Gathe, Robin Wood, Ian Sanne, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 10, 2004
A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir and lamivudine for treatment of HIV-infected patients
Robin Wood, Joseph Eron, Keikawus Arasteh, et al.
Antimicrobial Agents and Chemotherapy
|
December 25, 2003
Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients
Robin Wood, Keikawus Arasteh, Hans-Jürgen Stellbrink, et al.
Antimicrobial Agents and Chemotherapy
|
February 19, 2002
Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors
Michael Maguire, Denise Shortino, Astrid Klein, et al.
Lancet (London, England)
|
August 8, 2006
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial
Joseph Eron, Patrick Yeni, Joseph Gathe, et al.
The Journal of Infectious Diseases
|
December 11, 2012
Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study
Joseph J Eron, Bonaventura Clotet, Jacques Durant, et al.
The Journal of Antimicrobial Chemotherapy
|
June 12, 2009
Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance
Jean-Michel Molina, Mounir Ait-Khaled, Roberto Rinaldi, et al.
Page
of 1